The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Jointly Announce Availability of $3.5 Million in Fall 2018 Research Funding to Expand Understanding of the GBA gene in Parkinson’s Disease New York...
Prevail Therapeutics Announces $75 Million Series A Financing to Advance Gene Therapies for Patients with Parkinson’s and Other Neurodegenerative Diseases New York, NY – March 8, 2018 – Prevail Therapeutics, Inc. (Prevail), a biotechnology company developing gene...
The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox Foundation for Parkinson’s Research Hold Workshop to Accelerate GBA Therapeutic Development NEW YORK – March 9, 2018 – The Silverstein Foundation for Parkinson’s with GBA and The Michael J. Fox...
April, 2017—Two decades of successful investing in some of biotech’s biggest hits has made Jonathan Silverstein rich. Now he is looking for investments that could save his life.
August, 2017—Health care venture capitalist Jonathan Silverstein has more than two decades of professional experience with strategic investment in drug development. However, Jonathan’s sense of urgency to find cures intensified after he received a diagnosis...
